Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of FLAG-Ida As Frontline Therapy in a Pediatric AML Population: A Single Institution Experience

Andrew Doan, Holly K.T. Huang, Ari J. Hadar, Jemily Malvar, Teresa Rushing, Gordana Raca, Alexandra E. Kovach, Paul Gaynon, Etan Orgel

Blood (2021) 138 (Supplement 1): 2342.

https://doi.org/10.1182/blood-2021-148965

Published: 2021

Journal Articles

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

Weili Sun, Timothy Triche, Jr, Jemily Malvar, Paul Gaynon, Richard Sposto, Xiaojing Yang, Henrique Bittencourt, Andrew E. Place, Yoav Messinger, Chris Fraser, Luciano Dalla-Pozza, Bodour Salhia, Peter Jones, Alan S. Wayne, Lia Gore, Todd M. Cooper, Gangning Liang

Blood (2018) 131 (10): 1145–1148.

https://doi.org/10.1182/blood-2017-09-803809

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

Todd Michael Cooper, Jemily Malvar, M.S., Jeannette Cassar, Elena Eckroth, CCRC, Richard Sposto, PhD, Paul Gaynon, MD, Steven Dubois, MD, Lia Gore, MD, Margaret E. Macy, M.D., Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Javier Oesterheld, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2013) 122 (21): 624.

https://doi.org/10.1182/blood.V122.21.624.624

Published: 2013

Journal Articles

Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia

Fatih M. Uckun, Sanjive Qazi, Ingrid Cely, Kazim Sahin, Anoush Shahidzadeh, Ibrahim Ozercan, Qian Yin, Paul Gaynon, Amanda Termuhlen, Jianjun Cheng, Seang Yiv

Blood (2013) 121 (21): 4348–4354.

https://doi.org/10.1182/blood-2012-11-470633

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Todd Cooper, DO, Richard Sposto, PhD, Jeannette Cassar, Elena Eckroth, CCRC, Jemily Malvar, M.S., Paul Gaynon, MD, Steven Dubois, MD, Bill H Chang, MD, PhD, Lia Gore, MD, Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD

Blood (2012) 120 (21): 3605.

https://doi.org/10.1182/blood.V120.21.3605.3605

Published: 2012

Journal Articles

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Yoav H Messinger, MD, Paul Gaynon, MD, Richard Sposto, Ph.D., Jeannette van der Giessen, BA, CCRP, Elena Eckroth, CCRC, Jemily Malvar, M.S., Bruce C. Bostrom, MD

Blood (2011) 118 (21): 251.

https://doi.org/10.1182/blood.V118.21.251.251

Published: 2011

Journal Articles

Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,

Etan Orgel, MD, Richard Sposto, Ph.D., Jemily Malvar, M.S., Nita L. Seibel, MD, Elena J. Ladas, MS, RD, Paul Gaynon, MD, David R. Freyer, DO, MS

Blood (2011) 118 (21): 3574.

https://doi.org/10.1182/blood.V118.21.3574.3574

Published: 2011

Journal Articles

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

Nobuko Hijiya, MD, Jo-Anne Paul, Michael J. Borowitz, MD, PhD, Blythe Thomson, MD, Michael Isakoff, MD, Lewis B. Silverman, MD, Peter G Steinherz, MD, Richard Kadota, MD, Joseph G Pressey, MD, Violet Shen, MD, Roland Chu, MD, Todd Cooper, DO, Sima Jeha, MD, Bassem I. Razzouk, MD, Michael E. Rytting, MD, Elly Barry, MD, MMSc, William L. Carroll, MD, Paul Gaynon, MD

Blood (2010) 116 (21): 866.

https://doi.org/10.1182/blood.V116.21.866.866

Published: 2010

Journal Articles

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock, Mei La, Ben Sanford, Clara D. Bloomfield, James W. Vardiman, Paul Gaynon, Richard A. Larson, James Nachman

Blood (2008) 112 (5): 1646–1654.

https://doi.org/10.1182/blood-2008-01-130237

Published: 2008

Journal Articles

A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia.

Nobuko Hijiya, MD, Paul Gaynon, MD, Manuel Fernandez, Michael Rytting, MD, Roland Chu, MD, Elly Barry, MD, Blythe Thomson, MD, Todd Cooper, MD, Richard Kadota, MD, Stanley Chaleff, MD, Peter Steinherz, MD, Rekha Abichandani, MD, William Carroll, MD

Blood (2007) 110 (11): 883.

https://doi.org/10.1182/blood.V110.11.883.883

Published: 2007

Journal Articles

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Richard H. Ko, MD, Lingyun Ji, MS, Richard Sposto, PhD, Phillip Barnette, MD, Bruce Bostrom, MD, Raymond Hutchinson, MD, Elizabeth Raetz, MD, Nita Seibel, MD, Clare Twist, MD, Elena Eckroth, BA, Paul Gaynon, MD, Mignon Loh, MD

Blood (2007) 110 (11): 854.

https://doi.org/10.1182/blood.V110.11.854.854

Published: 2007

Journal Articles

Factors Influencing Survival after Relapse from Childhood ALL: A Children’s Oncology Group Study.

Kim Nguyen, Su-Chun Cheng, Ph.D, Elizabeth Raetz, M.D., Harland Sather, Ph.D, William L. Carroll, M.D., Naomi Winick, M.D., Stephen P. Hunger, M.D., Paul Gaynon, M.D., Mignon L. Loh, M.D.

Blood (2006) 108 (11): 1855.

https://doi.org/10.1182/blood.V108.11.1855.1855

Published: 2006

Journal Articles

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Cecilia H. Fu, MD, Janet L. Franklin, MD, Paul Gaynon, MD, Colleen McCarthy, RN, Edward Panosyan, MD, Stuart E. Siegel, MD, Vassilios I. Avramis, MD

Blood (2006) 108 (11): 4536.

https://doi.org/10.1182/blood.V108.11.4536.4536

Published: 2006

Journal Articles

Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies.

Sima Jeha, Bassem Razzouk, Paul Gaynon, Michael Rytting, Richard Kadota, Susan Rheingold, Lori Luchtman-Jones, Robert Arceci, Peter Steinherz

Blood (2006) 108 (11): 4460.

https://doi.org/10.1182/blood.V108.11.4460.4460

Published: 2006

Journal Articles

Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study

James A. Whitlock, Harland N. Sather, Paul Gaynon, Leslie L. Robison, Robert J. Wells, Michael Trigg, Nyla A. Heerema, Smita Bhatia

Blood (2005) 106 (13): 4043–4049.

https://doi.org/10.1182/blood-2003-10-3446

Published: 2005

Journal Articles

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Janet Franklin, MD, MPH, Staci Larsen, BA, Fred Dorey, PhD, Anna Butturini, MD, Cecelia Fu, MD, Beverly Lange, MD, Harland Sather, PhD, Paul Gaynon, MD

Blood (2004) 104 (11): 1958.

https://doi.org/10.1182/blood.V104.11.1958.1958

Published: 2004

Journal Articles

Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies.

Anna Butturini, MD, Fred Dorey, PhD, Paul Gaynon, MD, Cecilia Fu, MD, Janet Franklin, MD, Stuart Siegel, MD, Nancy Sacks, RN, Nita Siebel, MD, David Henry, MD, Paul Rogers, MD, Beverly Lange, MD, Harland Sather, PhD, Michael Trigg, MD, Archie Bleyer, MD

Blood (2004) 104 (11): 992.

https://doi.org/10.1182/blood.V104.11.992.992

Published: 2004

Journal Articles

Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Fatih M. Uckun, Zhiwen Yang, Harland Sather, Peter Steinherz, James Nachman, Bruce Bostrom, Lisa Crotty, Mireille Sarquis, Onur Ek, Tamer Zeren, David Tubergen, Gregory Reaman, Paul Gaynon

Blood (1997) 89 (10): 3769–3777.

https://doi.org/10.1182/blood.V89.10.3769

Published: 1997

Journal Articles

Clinical Features and Treatment Outcome of Children With Biphenotypic CD2 + CD19 + Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Fatih M. Uckun, Paul Gaynon, Harland Sather, Diane Arthur, Michael Trigg, David Tubergen, James Nachman, Peter Steinherz, Martha G. Sensel, Gregory R. Reaman

Blood (1997) 89 (7): 2488–2493.

https://doi.org/10.1182/blood.V89.7.2488

Published: 1997

NARROW

Efficacy and Safety of FLAG-Ida As Frontline Therapy in a Pediatric AML Population: A Single Institution Experience

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study

Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,

Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia.

Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.

Factors Influencing Survival after Relapse from Childhood ALL: A Children’s Oncology Group Study.

A Phase I Study of Oral 6-Thioguanine, Followed by Continuous Infusion Cytarabine, Followed by Intramuscular PEG-Asparaginase (“TGAP”) in Children with Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma.

Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies.

Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies.

Cellular Expression of Antiapoptotic BCL-2 Oncoprotein in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Clinical Features and Treatment Outcome of Children With Biphenotypic CD2 + CD19 + Acute Lymphoblastic Leukemia: A Children's Cancer Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only